Accarino John J O, Ramsey Allison, Samarakoon Upeka, Phillips Elizabeth, Gonzalez-Estrada Alexei, Otani Iris M, Fu Xiaoqing, Banerji Aleena, Stone Cosby A, Khan David A, Blumenthal Kimberly G
Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Rochester Regional Health, Rochester, New York; Department of Allergy/Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York.
Ann Allergy Asthma Immunol. 2023 Nov;131(5):628-636.e2. doi: 10.1016/j.anai.2023.07.024. Epub 2023 Aug 7.
Older adults have an increased risk of adverse drug reactions and negative effects associated with alternative antibiotic use. Although the number of antibiotic allergies reported increases with age, the characteristics and outcomes of older adults receiving drug allergy assessment are unknown.
To assess the characteristics and outcomes of drug allergy evaluations in older adults.
We considered patients aged above or equal to 65 years enrolled in the United States Drug Allergy Registry (USDAR), a US multisite prospective cohort (January 16, 2019 to February 28, 2022). Data were summarized using descriptive statistics.
Of 1678 USDAR participants from 5 sites, 406 older adults aged above or equal to 65 years (37% 65-69 years, 37% 70-74 years, 16% 75-79 years, and 10% ≥80 years) received 501 drug allergy assessments. USDAR older adults were primarily of female sex (69%), White (94%), and non-Hispanic (98%). Most USDAR older adults reported less than or equal to 1 infections per year (64%) and rated their general health as good, very good, or excellent (80%). Of 296 (59%) penicillin allergy assessments in USDAR older adults, 286 (97%) were disproved. Other drug allergy assessments included sulfonamide (n = 41, 88% disproved) and cephalosporin (n = 20, 95% disproved) antibiotics. All 41 drug allergy labels in USDAR participants aged above or equal to 80 years and all 80 penicillin allergy labels in USDAR men aged above or equal to 65 years were disproved.
Older adults represented a quarter of USDAR participants but were neither racially nor ethnically diverse and were generally healthy without considerable antibiotic need. Most older adults presented for antibiotic allergy assessments, the vast majority of which were disproved. Drug allergy assessments may be underutilized in the older adults who are most vulnerable to the harms of unconfirmed antibiotic allergy labels.
老年人发生药物不良反应以及使用替代抗生素相关负面影响的风险增加。尽管报告的抗生素过敏数量随年龄增长而增加,但接受药物过敏评估的老年人的特征和结果尚不清楚。
评估老年人药物过敏评估的特征和结果。
我们纳入了美国多中心前瞻性队列研究美国药物过敏登记处(USDAR,2019年1月16日至2022年2月28日)中年龄在65岁及以上的患者。数据采用描述性统计进行总结。
来自5个地点的1678名USDAR参与者中,406名年龄在65岁及以上的老年人(37%为65 - 69岁,37%为70 - 74岁,16%为75 - 79岁,10%为80岁及以上)接受了501次药物过敏评估。USDAR的老年人主要为女性(69%)、白人(94%)和非西班牙裔(98%)。大多数USDAR的老年人报告每年感染次数少于或等于1次(64%),并将他们的总体健康状况评为良好、非常好或优秀(80%)。在USDAR老年人的296次(59%)青霉素过敏评估中,286次(97%)被排除。其他药物过敏评估包括磺胺类抗生素(n = 41,88%被排除)和头孢菌素类抗生素(n = 20,95%被排除)。USDAR中所有80岁及以上参与者的41个药物过敏标签以及所有65岁及以上男性USDAR参与者的80个青霉素过敏标签均被排除。
老年人占USDAR参与者的四分之一,但在种族和民族上并不多样化,且总体健康,对抗生素的需求不大。大多数老年人进行了抗生素过敏评估,其中绝大多数被排除。在最易受未确诊抗生素过敏标签危害的老年人中,药物过敏评估可能未得到充分利用。